Although we haven’t gotten there just yet it’s no longer a question of if Type 2’s start using CGM but when they do and how they use it. CGM is not like an insulin pump when it comes to having a finite market size. CGM is valuable tool regardless of whether the patient uses insulin.
What’s misunderstood about CGM usage in the less intensive patient population is how they will use CGM and what it will cost. Let’s handle the cost question first as for CGM to penetrate the less intensive market sensors must achieve . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.